雜志介紹

Journal Of Infection And Chemotherapy雜志介紹

《Journal Of Infection And Chemotherapy》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱感染與化療雜志，本刊主要出版、報道醫(yī)學-INFECTIOUS DISEASES領域的研究動態(tài)以及在該領域取得的各方面的經(jīng)驗和科研成果，介紹該領域有關本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學術信息交流，提高行業(yè)發(fā)展。該刊已被國際權威數(shù)據(jù)庫SCIE收錄，為該領域相關學科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為1.9，最新CiteScore 指數(shù)為4.1。

本刊近期中國學者發(fā)表的論文主要有：

• A wide clinical spectrum of pulmonary affection in subjects with community-acquired Klebsiella pneumoniae liver abscess (CA-KPLA)

  Author: Zhu, Ziwen; Zhang, Beilei; Wang, Yang; Jing, Suxian; Ning, Weiwei; Liu, Chao; Chen, Cheng

• Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma

  Author: Zhou, Dian; Wang, Ying; Cheng, Hai; Zhu, Lili; Chen, Wei; Li, Hujun; Zhang, Xiaotian; Xia, Jieyun; Qi, Yuekun; Ma, Sha; Zhu, Feng; Yan, Zhiling; Qi, Kunming; Sang, Wei; Sun, Haiying; Li, Depeng; Cao, Jiang; Li, Zhenyu; Xu, Kailin

• Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021

  Author: Liu, Xin; Xu, Ze; Ma, Juman; Zhang, Aijun; Li, Zhaohang; Qi, Guanpeng; Li, Zuojing; Wei, Fenfang; Zhong, Ling

• Analysis of the epidemiological trends of enterovirus A in Asia and Europe

  Author: Qiao, Xiaorong; Liu, Xiaolan; Wang, Yan; Li, Yuhan; Wang, Lulu; Yang, Qingru; Wang, Hua; Shen, Hongxing

英文介紹

Journal Of Infection And Chemotherapy雜志英文介紹

The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.